Research progress on factor XI as a novel target for antithrombotic therapy / 中国药理学通报
Chinese Pharmacological Bulletin
; (12): 619-622, 2015.
Article
em Zh
| WPRIM
| ID: wpr-464380
Biblioteca responsável:
WPRO
ABSTRACT
Thromboembolic diseases are major health problems worldwide,and remain the leading cause of mortality and disabil-ity at present.Bleeding is the most important complication of an-tithrombotic therapy for thromboembolism,therefore research and development of new antithrombotic drugs with lowered bleeding risk is a significant medical need.The data that elevated plasma levels of FXI are associated with thromboembolic diseases,se-vere FXI deficiency reduced incidence of DVT and ischemic stroke,and FXI deficiency or inhibition in animals shows protec-tive effects against thrombus formation supporting FXI as a novel antithrombotic target with lowered bleeding risk.This paper re-views the progress on FXI as a novel antithrombotic target and the inhibitors target FXI.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Pharmacological Bulletin
Ano de publicação:
2015
Tipo de documento:
Article